(1) Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (2) 2007 addend(1) Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (2) 2007 addendum.National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Sep. 62 p. (Technology appraisal guidance; no. 111).Patients who continue on the drug should be reviewed every 6 months by MMSE score and global, functional, and behavioural assessment. Carers' views on the patient's condition at follow-up should be sought. The drug should only be continued while the patient's MMSE score remains at or above 10 points and their global, functional, and behavioural condition remains at a level where the drug is considered to be having a worthwhile effect. Any review involving MMSE assessment should be undertaken by an appropriate specialist team, unless there are locally agreed protocols for shared care.
